The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and children aged 9 years and older.

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

I also compiled expert-recommended hair thickening shampoos, treatments and more, plus highly rated products with dermatologist-approved hair thickening formulas. The experts I spoke to agree that ...

By elevating patient perspectives from an afterthought to a core part of the process, payers can create a system that aligns ...

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers ...

For patients with genital psoriasis, apremilast improved genital Physician Global Assessment scores, itch, and quality of life with a tolerable safety profile.

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

Roivant has its own TYK2/JAK1 inhibitor in development in the form of brepocitinib, which the biopharma licensed from Pfizer ...

Find out if gene therapy has also find its way into skin diseases. With two approvals in the last 2 years, is it the start of ...

Though cosmetic procedures like injectable fillers can offer a more effective long-term treatment, plenty of over-the-counter skin care products can help remedy discoloration over time.

Residual inflammation persisted among patients with psoriasis despite optimal disease response to biologic therapies, putting ...